Replies to post #176578 on Anavex Life Sciences Corp (AVXL)

[OFP]

Ignore the clinical and preclinical studies showing AVXL 2-73 to be more effective than the S1 agonists already on the market and worry that all of those studies are meaningless

Well your framing certainly explains a lot. Why don't you point to the "preclinical studies showing AVXL 2-73 to be more effective than the S1 agonists already on the market". I've been asking people to point to those for a long time.